Trial reportBone marrow transplantation2015
Identification and validation of biomarkers associated with acute and chronic graft versus host disease.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.Frontiers in immunology · 2022Pooled it
- A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD.Annals of hematology · 2025Trial
- Trial
- Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation.Scientific reports · 2021Trial
- Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.Blood · 2020Trial
- B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.Bone marrow transplantation · 2017Trial
- Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.Blood · 2017Trial
- Utilization of Clinical Data and Evaluation of Biomarkers in the Investigation of Graft-Versus-Host Disease Outcomes.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Current status, challenges, and integration pathways of biomarker classification systems in graft-versus-host disease: a preliminary exploration.Frontiers in medicine · 2025Review
- Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Transplantation and cellular therapy · 2024Review
- Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.Frontiers in immunology · 2024Review
- Targeting the chemokines in acute graft-versus-host disease.Frontiers in immunology · 2024Review
- A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.Blood advances · 2023Article
- Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation.Frontiers in immunology · 2023Article
- Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.Transplantation and cellular therapy · 2022Review
- Prospective external validation of biomarkers to predict acute graft-versus-host disease severity.Blood advances · 2022Article
- RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea.Blood advances · 2022Article
- Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.Frontiers in immunology · 2022Review
- Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.Transplantation and cellular therapy · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft versus host disease (GVHD) is a major complication of haematopoietic SCT (HSCT). A number of inflammatory cytokines/chemokines are implicated in GVHD and have been identified in numerous single centre studies as potential biomarkers for acute and/or chronic GVHD. In this study, we analysed candidate inflammatory biomarkers (B-cell activating factor (BAFF), interleukin 33 (IL-33), CXCL10 and CXCL11) in a two-centre study. Biomarkers were evaluated pre-transplant and at serial time points post transplant in acute and chronic GVHD patient sera with time-matched control samples from patients without GVHD. Further validation was performed using the human skin explant assay, clinical GVHD biopsies and mRNA expression analysis. BAFF was significantly increased pre-transplant. BAFF, IL-33, CXCL10 and CXCL11 showed increased levels in acute GVHD patient sera and high protein expression in grades II-III of the in vitro skin explant graft versus host reaction (GVHR) group. BAFF, CXCL10 and CXCL11 also showed increased mRNA expression levels in clinical biopsies compared with the no/low-grade GVHD group. BAFF, CXCL10 and CXCL11 levels were increased in chronic GVHD patient sera. The results identify BAFF and CXCL10 as predictive biomarkers for acute GVHD and BAFF, CXCL10 and CXCL11 as useful diagnostic biomarkers for acute GVHD and chronic GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.